Massivemarkets

ADMA

ADMA Biologics, Inc.

Nasdaq · usd

$10.75-0.20 (-1.83%)
As of 9:12:01 AM EDT on Oct 23, 2026 · 15-minute delayed

ADMA Biologics, Inc. (ADMA) trades at $10.75 (-1.83%) as of 9:12:01 AM EDT on Oct 23, 2026, +12.89% over the past month. Market cap is $2.45B, with 5.7 days to cover in short interest.

Stock performance

How ADMA Biologics, Inc. (ADMA) stock has performed from one day to one year, with its 52-week range.

-1.09%
-$0.12 over 1D
$10.89$10.92$10.96$10.996:55 AM8:05 AM$10.88
1D
-0.54%
1W
+2.05%
1M
+12.89%
YTD
-39.97%
1Y
-27.87%
52-wk range
$7.21 – $20.46

Key statistics

Today's trading snapshot for ADMA: day range, open, previous close, volume and market cap.

Day range
$10.80 – $11.11
Open
$11.01
Prev close
$10.95
Volume
3.55M
Market cap
$2.45B
Shares out
223.98M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for ADMA Biologics, Inc.: P/E, P/S, P/B, ROE and more.

P/E
14.52
P/S
4.79
P/B
6.01
P/FCF
21.06
ROE
41.4%
ROA
24.7%
Debt/Equity
0.48
Div yield
0.00%

As of Oct 22, 2026

8-K filings

Material corporate events ADMA Biologics, Inc. has disclosed to the SEC on Form 8-K.

  • Shareholder meetingsJun 2, 2026

    At the Annual Meeting, (i) the two Class I directors were elected, (ii) the appointment of the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified, and (iii) the Say-on-Pay proposal was approved.

  • Business developmentsMay 4, 2026

    the U.S. Food and Drug Administration has approved the Company's label expansion supplemental Biologics License Application for ASCENIV™ to include pediatric immune compromised patients two years of age and older.

  • Shareholder returnsMar 2, 2026

    On March 2, 2026, the Company entered into an accelerated share repurchase agreement (the "ASR Agreement") with JPMorgan Chase Bank, National Association ("JPMorgan") to repurchase $125 million of shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), as part of the Company's previously announced $500 million share repurchase program (the "Share Repurchase Program"), as disclosed on the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 7, 2025.

  • Executive leadershipFeb 25, 2026

    On February 25, 2026, the Board of Directors of the Company (the "Board") promoted Mr. Kohler to Chief Financial Officer and Treasurer of the Company, effective February 26, 2026. Mr. Kohler, age 48, joined the Company in December 2025 as its Executive Financial Advisor.

  • Investor communicationsJan 12, 2026

    The Company hereby furnishes the Corporate Presentation the Company expects to present, in whole or in part, and possibly with modifications, from time to time in connection with presentations to potential investors, strategic partners, industry analysts and others. The Corporate Presentation is attached hereto as Exhibit 99.2.

ADMA short interest

How heavily ADMA is shorted: shares short, days to cover and average daily volume.

Days to cover
5.7
Short interest
20.6M
Avg volume
3.63M

As of · reported to FINRA twice monthly.

ADMA news

The latest news and headlines about ADMA Biologics, Inc. (ADMA).

Frequently asked questions

What is the ADMA Biologics, Inc. (ADMA) stock price today?

ADMA Biologics, Inc. (ADMA) is trading at $10.75 (-1.83% on the day) as of 9:12:01 AM EDT on Oct 23, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is ADMA Biologics, Inc.?

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious…

What is the short interest in ADMA?

As of Sep 30, 2026, ADMA has 20.6M shares short and 5.7 days to cover.

What exchange is ADMA listed on?

ADMA Biologics, Inc. (ADMA) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

Build with AI

Build an analysis of ADMA with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a ADMA analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Want the most up-to-date, real-time data? Connect to the Massive API and MCP server — the source behind every number on this page — covering stocks, options, indices, currencies and futures. Docs: https://massive.com/docs/rest. Get a free API key.

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.